Compare QUAD & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUAD | CUVL |
|---|---|---|
| Founded | 1971 | N/A |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Publishing | Miscellaneous |
| Sector | Consumer Discretionary | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.3M | 374.2M |
| IPO Year | 2010 | N/A |
| Metric | QUAD | CUVL |
|---|---|---|
| Price | $10.39 | $6.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.93 | N/A |
| AVG Volume (30 Days) | ★ 404.7K | 11.9K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 5.71% | N/A |
| EPS Growth | ★ 150.47 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $2,419,900,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $77.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.12 | $5.95 |
| 52 Week High | $11.15 | $8.20 |
| Indicator | QUAD | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 39.69 |
| Support Level | $9.66 | N/A |
| Resistance Level | $11.15 | $7.04 |
| Average True Range (ATR) | 0.26 | 0.43 |
| MACD | -0.05 | -0.12 |
| Stochastic Oscillator | 95.14 | 11.11 |
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.